Moderna

Moderna is a publicly traded biotechnology company (NASDAQ: MRNA) that pioneered messenger-RNA (mRNA) medicines, reaching global scale with its COVID-19 vaccine and building a pipeline across infectious disease, oncology, and rare disease. It is included here not as an AI vendor but as one of the most-cited enterprise AI adopters in the life sciences: Moderna has deployed AI deeply across the business — reportedly 750-plus internal AI models, an organization-wide ChatGPT Enterprise rollout, and a partnership with OpenAI — to accelerate mRNA sequence design, optimize manufacturing, and run leaner operations.

The honest framing is the important part. Moderna does not sell an AI product; its value derives from its mRNA platform, pipeline, and manufacturing, with AI as an internal accelerant rather than a revenue line. That makes it a useful teaching example of the "AI adopter" pattern — how a science-and-manufacturing company uses AI as a horizontal productivity and R&D tool — and a contrast to the AI-native drug-discovery companies (such as Recursion or Insilico) whose core product is the AI platform itself. One product line complicates that adopter framing slightly, and it is worth stating precisely. Moderna's individualized neoantigen therapy, developed with Merck, uses what the company describes as a proprietary algorithm to review the mutations found by sequencing a patient's tumor and predict up to 34 targets to build each dose against. In August 2026 the pair reported that the therapy met its primary endpoint in a Phase 3 melanoma trial — the first positive Phase 3 readout for an individualized neoantigen therapy. The honest reading is narrow: an automated selector is not necessarily a learned machine-learning system, Moderna states the learning ambition in the conditional (the algorithm has the *potential* to learn over time), and Merck's own Phase 3 materials describing the result do not credit AI at all. The clinical benefit is attributable to messenger RNA delivery and neoantigen biology; the algorithm chooses targets. It is a real computational step inside a real therapy, not an AI cure.

For learners, Moderna illustrates that the biggest near-term AI impact in many industries comes from adoption inside incumbents, not only from new AI-first entrants.